Biogen has given an update on the rollout of its Eisai-partnered Alzheimer’s disease therapy Leqembi alongside its first-quarter results, showing that while the drug’s take-up is building it remains slow going.
In-market sales were $19 million in the quarter, up from $7 million in the fourth quarter and $10 million for 2023 as a whole, with a 2.5-fold increase in the number of patients currently on treatment with the anti-amyloid drug.
